GlassScriptPhysician profile
Eugene Gabianelli
NPI 1104838697
$3,633.37
in general payments reported to CMS, 2019-2025
26 companies · $349 in 2025
The $349 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $531 · 2021: $358 · 2022: $479 · 2023: $379 · 2024: $305 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,483.13 | 2019-2025 | Hydrus Microstent, Clareon, Voyager Dslt |
| Sun Pharmaceutical Industries INC. | $377.90 | 2019-2025 | Cequa |
| Abbvie INC. | $314.73 | 2022-2025 | |
| Allergan, INC. | $266.89 | 2019-2022 | |
| Eyepoint US, INC. | $250.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $184.11 | 2019-2022 | |
| Rxsight INC | $137.56 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Mallinckrodt Hospital Products INC. | $124.06 | 2021 | |
| Omeros Corporation | $56.62 | 2019 | |
| Kala Pharmaceuticals, INC. | $55.35 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $48.20 | 2022-2025 | Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $39.23 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $39.00 | 2022-2023 | Prolensa, Vyzulta, Lotemax Sm |
| Tarsus Pharmaceuticals, INC. | $36.28 | 2024 | Xdemvy |
| Lensar, INC. | $34.60 | 2024 | Lensar Laser System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.00 | 2024 | Tepezza |
| Dompe US, INC. | $21.06 | 2019 | |
| Harrow Eye, LLC | $20.43 | 2024 | Vevye |
| Ocular Therapeutix, INC. | $19.59 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Biotissue Holdings INC. | $17.24 | 2023 | |
| Sight Sciences, INC. | $17.18 | 2023 | Omni Surgical System |
| Mallinckrodt Enterprises LLC | $17.11 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.82 | 2019 | |
| Oyster Point Pharma, INC. | $14.04 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Gabianelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.